NCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT03618550 2025-12-02
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03443128 2025-02-13
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
Phase 2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03397953 2022-07-26
Vinorelbine for Recurrent ACLC
Children's Cancer Group, China
Phase 2 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT00006029 2016-07-14
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT00006760 2013-07-26
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00070304 2013-07-26
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed